Your browser is no longer supported. Please, upgrade your browser.
BNTC Benitec Biopharma Limited daily Stock Chart
Benitec Biopharma Limited
Index- P/E- EPS (ttm)-0.90 Insider Own- Shs Outstand205.14M Perf Week0.00%
Market Cap473.88M Forward P/E- EPS next Y- Insider Trans- Shs Float5.96M Perf Month20.31%
Income- PEG- EPS next Q- Inst Own- Short Float2.42% Perf Quarter-12.50%
Sales7.68M P/S61.70 EPS this Y- Inst Trans- Short Ratio2.34 Perf Half Y29.05%
Book/sh1.80 P/B1.28 EPS next Y- ROA- Target Price14.00 Perf Year86.29%
Cash/sh- P/C- EPS next 5Y- ROE- 52W Range1.30 - 5.48 Perf YTD50.98%
Dividend- P/FCF- EPS past 5Y- ROI- 52W High-57.85% Beta-
Dividend %- Quick Ratio- Sales past 5Y- Gross Margin- 52W Low77.69% ATR0.13
Employees- Current Ratio- Sales Q/Q4.40% Oper. Margin- RSI (14)60.96 Volatility2.96% 5.75%
OptionableNo Debt/Eq- EPS Q/Q- Profit Margin- Rel Volume0.14 Prev Close2.34
ShortableYes LT Debt/Eq- Earnings- Payout- Avg Volume61.63K Price2.31
Recom3.00 SMA2012.64% SMA507.12% SMA2008.56% Volume8,677 Change-1.28%
Feb-26-16Downgrade Maxim Group Buy → Hold
Dec-31-15Reiterated Maxim Group Buy $23 → $14
Sep-16-15Reiterated Maxim Group Buy $4 → $23
Apr-05-17 07:30AM  Today's Research Reports on Biotech Stocks to Watch: Benitec Biopharma and Paratek Pharmaceuticals -19.76%
Apr-04-17 04:40PM  Rising Biotechs: Paratek Among Stocks Surging On Trial Results +34.39%
08:00AM  Key pre-clinical data on oculopharyngeal muscular dystrophy (OPMD) published in Nature Communications
Mar-27-17 09:30AM  Increased Volume Spurs Stock Prices of Benitec Biopharma, Regulus Therapeutics Accesswire
Mar-13-17 06:00AM  Benitec Biopharma completes second tranche placement to Nant Capital to raise A$5.45 million PR Newswire
Feb-16-17 08:00AM  Benitec Biopharma to present expanded data set from pivotal data in hepatitis B virus (HBV) in vivo model at International Liver Meeting in Shanghai, China PR Newswire +6.02%
Feb-03-17 09:45AM  M&A Activity Could Kick Start Biotech Industry's Recovery in 2017: Today's Report on Benitec and Protalix Accesswire -28.80%
Feb-02-17 12:05PM  Why Benitec More Than Doubled +134.38%
07:00AM  Benitec Biopharma makes significant progress in ocular program PR Newswire
Jan-30-17 08:00AM  Benitec initiates development work on head and neck cancer programs after executing Collaboration Agreement with Nant Capital PR Newswire
Jan-18-17 09:30AM  Biotech Industry Outperforming Markets in 2017: Latest Reports on Benitec Biopharma and Tandem Diabetes Care Accesswire -21.51%
08:26AM  Benitec Stock Up on Orphan Drug Status for BB-301 in EU Zacks
08:15AM  Blog Coverage Benitec Biopharma Secures Orphan Drug Designation for its Product Treating Patients with Oculopharyngeal Muscular Dystrophy Accesswire
Jan-17-17 11:05AM  Tuesdays Top Biopharma Movers 24/7 Wall St. +62.16%
05:00AM  Benitec Receives Orphan Drug Designation in the European Union for BB-301, a ddRNAi Therapeutic in Development for the Treatment of Oculopharyngeal Muscular Dystrophy PR Newswire
Dec-23-16 06:00AM  Benitec in-licenses clinical program for head and neck cancer from NantWorks PR Newswire
Dec-20-16 07:00AM  Benitec releases pivotal data in an in vivo hepatitis B model PR Newswire +9.50%
Oct-24-16 07:10PM  Benitec initiates a strategic engagement with NantVentures Other +26.24%
Sep-23-16 11:34AM  Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: 2016 By the Numbers : September 23, 2016
Aug-10-16 05:00AM  Benitec announces restructuring of Senior Executive team PR Newswire
May-24-16 04:45AM  Benitec Biopharma Interim Report for the Nine Months Ended March 31, 2016 PR Newswire
May-17-16 05:00AM  Benitec Biopharma to Host Corporate Update Conference Call PR Newswire
Apr-25-16 08:30AM  Benitec to present at the ASGCT 2016 Annual Meeting PR Newswire
Mar-08-16 08:16AM  Benitec's Hepatitis B Therapy Reduces HBV DNA by 98.5% In Vivo PR Newswire +15.88%
Mar-07-16 02:29PM  Benitec Biopharma Ltd. :BNTC-US: Earnings Analysis: For the six months ended December 31, 2015
Feb-26-16 07:26AM  Benitec Biopharma downgraded by Maxim Group -55.14%
Feb-25-16 10:13PM  Benitec Biopharma Limited: Interim Report for the Half Year Ended December 31, 2015 PR Newswire
06:42PM  Update on TT-034 Hepatitis C Clinical Trial PR Newswire
Jan-29-16 07:36PM  Appendix 4C - quarterly Other
Dec-10-15 07:51PM  Benitec Biopharma to Host Corporate Update Conference Call PR Newswire
Dec-08-15 05:05PM  Greg West, Benitec's Chief Financial Officer and Company Secretary, Named Interim Chief Executive Officer PR Newswire -6.42%
Dec-07-15 08:00AM  Benitec's Hepatitis B Therapeutic Shows Positive Preclinical Results PR Newswire +11.97%
Oct-29-15 11:13AM  Why the Australian Dollar Fell on Weak Inflation
Oct-22-15 08:00AM  Benitec Biopharma's Abstract Accepted for Presentation at the AASLD Liver Meeting 2015 PR Newswire +12.01%
Oct-19-15 07:30AM  Benitec Forms Hepatology Clinical Advisory Board Other
Oct-14-15 08:00AM  Benitec Biopharma to Present at The 14th Annual BIO Investor Forum Other
Oct-07-15 07:00AM  Lonza and Benitec Enter Agreement to Develop Scalable AAV Manufacturing Process for ddRNAi Therapeutics PR Newswire
Sep-25-15 10:23AM  Benitec Biopharma rings Nasdaq opening bell at CNBC
Sep-24-15 10:00AM  Benitec Biopharma Limited (Nasdaq: BNTC) to Ring The Nasdaq Stock Market Opening Bell GlobeNewswire
Sep-23-15 08:00AM  Benitec Featured at CHI's "Discovery On Target" Conference PR Newswire
Sep-16-15 07:30AM  Benitec Initiates a Fourth Site in Hepatitis C Clinical Trial PR Newswire
Aug-24-15 07:30AM  Benitec Announces Closing Of An Initial Public Offering In The United States With Listing On NASDAQ PR Newswire
Aug-05-15 02:45PM  IPO Outlook: Planet Fitness Bargain Gym Memberships Growing Strong +8.91%
Developing gene therapies for hepatitis C based on RNA interference.